# Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06545942/  
OnCo record `nct06545942` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MOMA-313 run by MOMA Therapeutics, now recruiting.

## Summary

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06545942 by MOMA Therapeutics, with 220 participants planned, started 2024-08-13. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer and Homologous Recombination Deficiency. Interventions recorded: MOMA-313 and Olaparib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06545942
- Phase: 1
- Setting: A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
- Sponsor: MOMA Therapeutics
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06545942: https://clinicaltrials.gov/study/NCT06545942

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [MOMA-313](https://onco.cc/drugs/moma-313/)
- companies: [MOMA Therapeutics](https://onco.cc/companies/moma-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06545942.json